CIK 0001541157 · Non-accelerated filer<br>Smaller reporting company
Akari Therapeutics Plc
Sign in to watch- Ticker
- AKTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- EIN
- 981034922
- Phone
- (929) 274-7510
- Business address
- 401 EAST JACKSON STREET, SUITE 3300, TAMPA, FL, 33602
- Former names
- Celsus Therapeutics Plc., Morria Biopharmaceuticals PLC
- 4 Open-market buy President & CEO bought 6,146 shares at an average $1.16 ($7,120)
- 4 Open-market buy President & CEO bought 10,000 shares at $1.20 ($12,000)
- 4 Open-market buy President & CEO bought 15,000 shares at $1.20 ($18,000)
- 4 Grant or award CEO acquired 45,000 shares (grant or award)
- 4 Grant or award CEO acquired 20,000 shares (grant or award)
- ARS Other Annual Report to Security Holders
- DEF 14A Proxy Proxy Statement
- PRE 14A Proxy Proxy Statement (Preliminary)
- 8-K Event Results of operations
- EFFECT Other Notice of Effectiveness
- 10-Q Report Quarterly Report
- 424B3 Offering Prospectus
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- S-3 Offering Registration Statement
- 4 Grant or award Director acquired 44,642 shares (grant or award)
- 8-K Event Results of operations
- 10-K Report Annual Report
- NT 10-K Other NT 10-K
- 4 Derivatives Options or other derivatives
Page 6 of 38 · 746 filings